Impax Laboratories, Inc. Form 10-K for fiscal year 2016 (mebendazole product acquisition from Teva; Emverm launch) (2017)

Government Record · Impax Laboratories, Inc. (filed with the U.S. Securities and Exchange Commission) · March 1, 2017

Impax's annual report discloses that it bought Teva's mebendazole ANDA and regulatory assets, paid Teva $3.5 million on approval and launch in the first quarter of 2016, and owes Teva a royalty on Emverm net sales. It is the primary document for how the single US generic mebendazole product changed hands and who is paid on each sale.

we are required to pay certain milestone payments up to an aggregate amount of $3.5 million upon the approval and launch of the mebendazole tablet product; we paid the $3.5 million to Teva during the quarter ended March 31, 2016 upon the FDA's approval and our subsequent launch of Emverm

Impax's annual report discloses that it bought Teva's mebendazole ANDA and regulatory assets, paid Teva $3.5 million on approval and launch in the first quarter of 2016, and owes Teva a royalty on Emverm net sales. It is the primary document for how the single US generic mebendazole product changed hands and who is paid on each sale. SEC filing (company document hosted by a federal agency, hence LINK and Copyrighted, not public domain). Payment terms as stated by the company: milestone payments up to $3.5 million, paid in Q1 2016; ongoing royalty on Emverm net sales 'including a specified annual minimum royalty payment'. The same filing states Emverm (mebendazole) 100 mg chewable tablets were among products 'all acquired in our acquisition of Tower and Lineage which closed in March 2015'. This makes the chain: Teva ANDA -> Impax (2015-2016) -> Amneal (2018). Neutral disclosure of commercial terms; no inference about intent.